Latisse sales through the roof!

The Los Angeles Times reports, In an otherwise lackluster beauty industry lash enhancers are all the rage.


Allergan's lash enhancer, Latisse, is the first FDA-approved lash-growing product, which is available by prescription only. Latisse grossed $25.4 million in sales in the first half of this year, and the company says it anticipates doing $60 million in total by year's end.

Meanwhile, competitors, including Dr. Simon Ourian's Epione Lash RX...came out at the end of August and sold 1,000 units in its first couple of weeks. The products are designed to be brushed close to the upper and lower lashes before bedtime, and within a few weeks lashes appear thicker and longer. But, dermatologists warn about potential sensitivity. Jessica Wu, assistant clinical professor of dermatology at USC, cautioned that people have underlying conditions, so you need to talk to your eyecare provider before starting treatment.

Posted in: Allergan, Dermatology, Los Angeles, U.S. Food and Drug Administration